Aspirin, Ibuprofen, and the Risk for Colorectal Cancer in Lynch Syndrome

Ouakrim, Driss Ait, Dashti, Seyedeh Ghazaleh, Chau, Rowena, Buchanan, Daniel D., Clendenning, Mark, Rosty, Christophe, Winship, Ingrid M., Young, Joanne P., Giles, Graham G., Leggett, Barbara, Macrae, Finlay A., Ahnen, Dennis J., Casey, Graham, Gallinger, Steven, Haile, Robert W., Le Marchand, Loic, Thibodeau, Stephen N., Lindor, Noralane M., Newcomb, Polly A., Potter, John D., Baron, John A., Hopper, John L., Jenkins, Mark A. and Win, Aung Ko (2015) Aspirin, Ibuprofen, and the Risk for Colorectal Cancer in Lynch Syndrome. Journal of the National Cancer Institute, 107 9: . doi:10.1093/jnci/djv170

Author Ouakrim, Driss Ait
Dashti, Seyedeh Ghazaleh
Chau, Rowena
Buchanan, Daniel D.
Clendenning, Mark
Rosty, Christophe
Winship, Ingrid M.
Young, Joanne P.
Giles, Graham G.
Leggett, Barbara
Macrae, Finlay A.
Ahnen, Dennis J.
Casey, Graham
Gallinger, Steven
Haile, Robert W.
Le Marchand, Loic
Thibodeau, Stephen N.
Lindor, Noralane M.
Newcomb, Polly A.
Potter, John D.
Baron, John A.
Hopper, John L.
Jenkins, Mark A.
Win, Aung Ko
Title Aspirin, Ibuprofen, and the Risk for Colorectal Cancer in Lynch Syndrome
Journal name Journal of the National Cancer Institute   Check publisher's open access policy
ISSN 1460-2105
Publication date 2015-09-01
Year available 2015
Sub-type Article (original research)
DOI 10.1093/jnci/djv170
Open Access Status Not Open Access
Volume 107
Issue 9
Total pages 11
Place of publication Oxford, United Kingdom
Publisher Oxford University Press
Collection year 2016
Language eng
Formatted abstract
Background: Inheritance of a germline mutation in one of the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2 causes a high risk of colorectal and other cancers (Lynch Syndrome). Use of aspirin has been shown to be associated with a reduced risk of colorectal cancer for the general population as well as for MMR gene mutation carriers. The aim of this study was to determine whether use of aspirin and ibuprofen in a nontrial setting is associated with the risk of colorectal cancer risk for MMR gene mutation carriers.

Methods: We included 1858 participants in the Colon Cancer Family Registry who had been found to have a pathogenic germline mutation in a MMR gene (carriers). We used weighted Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided.

Results: A total of 714 carriers (38%) were diagnosed with colorectal cancer at a mean age of 42.4 (standard deviation 10.6) years. A reduced risk of colorectal cancer was associated with aspirin use (for 1 month to 4.9 years: HR = 0.49, 95% CI = 0.27 to 0.90, P = .02; for ≥5 years: HR = 0.25, 95% CI = 0.10 to 0.62, P = .003) and ibuprofen use (for 1 month to 4.9 years: HR = 0.38, 95% CI = 0.18 to 0.79, P = .009; for ≥5 years: HR = 0.26, 95% CI = 0.10 to 0.69, P = .007), compared with less than one month of use.

Conclusion: Our results provide additional evidence that, for MMR gene mutation carriers, use of aspirin and ibuprofen might be effective in reducing their high risk of colorectal cancer.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2016 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 6 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 06 Oct 2015, 02:04:16 EST by System User on behalf of Scholarly Communication and Digitisation Service